BusinessMadrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical AchievementsBy Nasdaq OMXMay 8, 2018, 10:50 AM UTC
BusinessMadrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196By Nasdaq OMXMar 13, 2018, 10:50 AM UTC
BusinessMadrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)By Nasdaq OMXFeb 8, 2018, 11:50 AM UTC
BusinessMadrigal Pharmaceuticals Prices Public Offering of Common StockBy Nasdaq OMXDec 19, 2017, 4:26 AM UTC
BusinessMadrigal Pharmaceuticals Announces Proposed Public Offering of Common StockBy Nasdaq OMXDec 18, 2017, 11:50 AM UTC
BusinessMadrigal Pharmaceuticals Reports 2017 Third Quarter Financial ResultsBy Nasdaq OMXNov 9, 2017, 12:50 PM UTC
BusinessMadrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver MeetingBy Nasdaq OMXOct 23, 2017, 11:00 AM UTC
BusinessNovelion Therapeutics Observes Familial Hypercholesterolemia Awareness DayBy Nasdaq OMXSep 24, 2017, 12:00 PM UTC
